The exploration of the mechanism underlying hypertension induced by antineoplastic drugs has suggested a correlation with ROS oxidative stress triggered by ET-1, which enhances NADPH oxidase activity and consequently elevates ROS production. The gene discussed is FMO5; the disease is hypertensive disorder.